Navigation Links
Unusual Trading Activity In Cardium Common Stock
Date:9/27/2013

www.cardiumthx.com/">www.cardiumthx.com.

Forward-Looking Statements  

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there is no assurance that clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the Company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that the Company will not be adversely affected by risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2013 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Concord Medical Responds to Unusual Market Activity in its Stock
2. K-V Pharmaceutical Company States That Its Policy is Not to Comment on Unusual Market Activity
3. Immune Pharmaceuticals Inc. Trading Symbol is Now IMNP on Both NASDAQ OMX Stockholm Exchange and OTCQX Trading Platform
4. Cannabis Science Announces The Depository Trust Company (DTC) Lifts Share Trading "Chill" Effective Immediately
5. TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace
6. PharmaRoth Labs, Inc. Announces Trading Symbol Change
7. NeuroVive Admitted to Trading on NASDAQ OMX Stockholm
8. PAREXEL International Provides Update On Share Repurchase Program, Announces A New $50 Million Accelerated Share Repurchase Agreement And A New $50 Million 10b5-1 Trading Plan
9. Trading of Depomed Common Stock Halted
10. Vasomedical Common Stock Commences Trading on the OTCBB
11. MetaStat Announces Stock Trading on OTC Bulletin Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs ... facility in Albany, NY for ... The company meets and/or exceeds the FDA standards for ... 21 CFR Part 211. The 10,000 ... highest levels of quality assurance and quality control. The ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Anlit Advanced Nutrition Supplements , an ... for children, will present new and innovative products at ... 2012 in Geneva, Switzerland. Anlit will showcase new ... at Stand 3500. The company will present, among others, ...
... 2012  Luminex Corporation (NASDAQ: LMNX ) today announced ...  Financial and operating highlights include the following: , ... increase over the first quarter of 2011 , First ... over the first quarter of 2011 , First quarter ...
Cached Medicine Technology:Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012 2Luminex Corporation Reports First Quarter 2012 Results 2Luminex Corporation Reports First Quarter 2012 Results 3Luminex Corporation Reports First Quarter 2012 Results 4Luminex Corporation Reports First Quarter 2012 Results 5Luminex Corporation Reports First Quarter 2012 Results 6Luminex Corporation Reports First Quarter 2012 Results 7Luminex Corporation Reports First Quarter 2012 Results 8
(Date:10/20/2014)... Myoderm announced today ... of their CentralSource service. Matthew will ... turnkey drug sourcing, distribution, and management service for ... years of industry experience, in both business development ... of their international success to help clients manage ...
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... 19, 2014 Visual Impact Frequency ... just been released to the public generating a ... building and fitness community. The commotion surrounding the ... Vin Delmonico prompting an investigative review. , "Many ... what is commonly known as a training 'plateau' ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... fruitful, lead in ongoing investigation into salmonella outbreak , , ... U.S. government investigation into salmonella-tainted tomatoes has not yet ... said Monday they are now focusing their trace-back efforts ... , "The cluster is linked to the same ...
... PITTSBURGH, June 16 Mylan Inc. (NYSE: ... Inc., has,received tentative approval from the U.S. Food ... Application (ANDA) for Irbesartan and,Hydrochlorothiazide Tablets, 150 mg/12.5 ... Hydrochlorothiazide Tablets, indicated for the treatment,of hypertension, are ...
... have found a new family of therapeutic agents that ... growth of breast cancer cells. The results of the ... The Endocrine Society,s 90th Annual Meeting in San Francisco. ... therapeutic called TPBM and related compounds are likely to ...
... of agents that inhibit the growth of estrogen-dependent breast ... of the Endocrine Society, has opened an avenue of ... , "This cell-based study is exciting because it suggests ... that remain dependent on estrogen for growth but are ...
... could be the next generation of treatments, researchers say ... identified a new group of compounds that might one ... to fight estrogen-fueled breast cancer. , "This is a ... Dr. Len Lichtenfeld, deputy chief medical officer of the ...
... June 16 The National Center for Healthcare,Leadership ... Gabow, MD, chief,executive officer of Denver Health, as ... for her significant and lasting contributions,to healthcare. Under ... healthcare system that achieves organizational,excellence while treating at-risk ...
Cached Medicine News:Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 2Health News:FDA Narrowing Tainted Tomato Probe to One Cluster 3Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:Team discovers new inhibitors of estrogen-dependent breast cancer cells 2Health News:New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 3Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 4
A lytic reagent manufactured for the simultaneous quantitative determinations of hemoglobin and white blood cells. Streck-Lysing Agent III is for use on the Abbott CELL-DYN® 1400 and 1600. The sh...
Streck-Diluent CD is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1800....
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... hematology control for the Abbott CELL-DYN 3000, ... for the five-part white cell differential, as ... CELL-DYN 1600 and 1700. Open-vial stability is ... days. Para 12 Plus is packaged in ...
Medicine Products: